Regeneron CEO: Manufacturing not up to snuff for COVID-19 vaccines, therapies

Regeneron has been at the forefront of the COVID-19 fight for months with partnered med Kevzara in clinical trials and an antibody cocktail in development. But success in the clinic means nothing if drugmakers can't produce a therapy or vaccine fast enough––and the company's helmsman is sounding the alarm.